Literature DB >> 23277077

Migration of retinal pigment epithelial cells is EGFR/PI3K/AKT dependent.

Lei Zhang1, Fenghua Wang, Yuan Jiang, Shan Xu, Fengqing Lu, Wenqiu Wang, Xiangjun Sun, Xiaodong Sun.   

Abstract

Abnormal migration of retinal pigment epithelium (RPE) contributes to a variety of disorders such as proliferative vitreoretinopathy. Here, the effect of epidermal growth factor (EGF), and signaling by its receptor (ERGR)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) on RPE cell migration was studied. The in vitro wound healing and migration of the human RPE cell line, ARPE19 cell was accelerated, in a dose dependent manner, in response to EGF stimulation, while pretreatment with EGFR, PI3K or AKT inhibitor, inhibited both events. Exposure of cells to EGF activated the AKT phosphorylation, whereas EGFR and PI3K inhibitors blocked EGF-induced AKT phosphorylation in a dose-dependent manner. These data suggest that EGF mediate ARPE-19 cell migration through EGFR/PI3K/AKT signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23277077     DOI: 10.2741/s398

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  10 in total

1.  Application of quantitative trait locus mapping and transcriptomics to studies of the senescence-accelerated phenotype in rats.

Authors:  Elena E Korbolina; Nikita I Ershov; Leonid O Bryzgalov; Natalia G Kolosova
Journal:  BMC Genomics       Date:  2014-12-19       Impact factor: 3.969

2.  Oxidative stress affects retinal pigment epithelial cell survival through epidermal growth factor receptor/AKT signaling pathway.

Authors:  Xiao-Dong Chen; Ming-Yang Su; Tao-Tao Chen; Hai-Yan Hong; Ai-Dong Han; Wen-Sheng Li
Journal:  Int J Ophthalmol       Date:  2017-04-18       Impact factor: 1.779

3.  Tumor-treating fields in combination with sorafenib restrain the proliferation of liver cancer in vitro.

Authors:  Yoonjung Jang; Won Seok Lee; Sei Sai; Jeong Yub Kim; Jong-Ki Kim; Eun Ho Kim
Journal:  Oncol Lett       Date:  2022-08-11       Impact factor: 3.111

4.  Differences in Intraretinal Pigment Migration Across Inherited Retinal Dystrophies.

Authors:  Jin Kyun Oh; Sarah R Levi; Joonpyo Kim; Jose Ronaldo Lima de Carvalho; Joseph Ryu; Janet R Sparrow; Stephen H Tsang
Journal:  Am J Ophthalmol       Date:  2020-05-20       Impact factor: 5.488

5.  Overexpression p21WAF1/CIP1 in suppressing retinal pigment epithelial cells and progression of proliferative vitreoretinopathy via inhibition CDK2 and cyclin E.

Authors:  Ying Wang; Zhigang Yuan; Caiyun You; Jindong Han; Haiyan Li; Zhuhong Zhang; Hua Yan
Journal:  BMC Ophthalmol       Date:  2014-11-25       Impact factor: 2.209

6.  Squamosamide derivative FLZ protects retinal pigment epithelium cells from oxidative stress through activation of epidermal growth factor receptor (EGFR)-AKT signaling.

Authors:  Li-Bo Cheng; Chun-Ming Chen; Hong Zhong; Li-Juan Zhu
Journal:  Int J Mol Sci       Date:  2014-10-17       Impact factor: 5.923

7.  Fisetin inhibits epidermal growth factor-induced migration of ARPE-19 cells by suppression of AKT activation and Sp1-dependent MMP-9 expression.

Authors:  Hung-Yu Lin; Yong-Syuan Chen; Kai Wang; Hsiang-Wen Chien; Yi-Hsien Hsieh; Shun-Fa Yang
Journal:  Mol Vis       Date:  2017-12-10       Impact factor: 2.367

8.  Compatibility of intravitreally applied epidermal growth factor and amphiregulin.

Authors:  Mukharram M Bikbov; Timur A Khalimov; Marc Cerrada-Gimenez; Symantas Ragauskas; Giedrius Kalesnykas; Jost B Jonas
Journal:  Int Ophthalmol       Date:  2021-03-13       Impact factor: 2.031

9.  The sonic hedgehog signaling pathway induces myopic development by activating matrix metalloproteinase (MMP)-2 in Guinea pigs.

Authors:  Minjie Chen; Yishan Qian; Jinhui Dai; Renyuan Chu
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

10.  Capsaicin and sorafenib combination treatment exerts synergistic anti‑hepatocellular carcinoma activity by suppressing EGFR and PI3K/Akt/mTOR signaling.

Authors:  Ninggao Dai; Ruifan Ye; Qikuan He; Pengyi Guo; Hao Chen; Qiyu Zhang
Journal:  Oncol Rep       Date:  2018-10-01       Impact factor: 3.906

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.